Dipti Baral
Pulmonary Disease · Ocean Springs, MSNPI 1275966137
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.0%), education and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Intuitive Surgical at 51.8% of the total. Reporting peaked in 2024 at $6,528 and has fallen 84.5% since, to $1,009 in 2025.
Across 322 payments — averaging $33.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- GSK$2K
- Johnson & Johnson$422
- United Therapeutics Corporation$335
- AstraZeneca$290
- Boehringer Ingelheim$281
- plus $2K from 26 others
What the payments were for
- Travel & lodging$1,79316%
- Food & beverage$5,02246%
- Education$4,09538%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $5,656 |
| GSK | 136 | $1,544 |
| Johnson & Johnson | 5 | $422 |
| United Therapeutics Corporation | 17 | $335 |
| AstraZeneca(2 entities) | 17 | $290 |
| Boehringer Ingelheim | 16 | $281 |
| Actelion Pharmaceuticals US, Inc. | 9 | $236 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $229 |
| Grifols USA, LLC | 9 | $201 |
| Mallinckrodt Hospital Products Inc. | 10 | $198 |
| Sanofi | 8 | $178 |
| Electromed, Inc. | 19 | $157 |
| Pulmonx Corporation | 4 | $136 |
| Merck | 6 | $128 |
| Baxter Healthcare | 4 | $125 |
| Paratek Pharmaceuticals, Inc. | 3 | $113 |
| Novartis | 5 | $107 |
| Insmed, Inc. | 5 | $97 |
| Mylan Specialty L.p. | 5 | $75 |
| Verona Pharma, Inc. | 3 | $57 |
| Bayer | 3 | $55 |
| AbbVie | 2 | $50 |
| La Jolla Pharmaceutical Company | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Astellas Pharma US Inc | 1 | $30 |
| Portola Pharmaceuticals, LLC | 2 | $30 |
| Inogen, Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Circassia Inc. | 1 | $18 |
| Philips North America LLC | 1 | $15 |
| Apria Healthcare LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,442
- Monarch Platform$372
How this compares
$10,909 in reported general payments places this provider in the 70th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 226 | $201,581 |
| Dupixent PenDupilumab | 51 | $195,107 |
| OpsumitMacitentan | 13 | $153,204 |
| Pirfenidone | 28 | $106,554 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 117 | $92,596 |
| NucalaMepolizumab | 11 | $40,945 |
| Breo ElliptaFluticasone/Vilanterol | 86 | $40,773 |
| Spiriva RespimatTiotropium Bromide | 39 | $39,322 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $28,020 |
| SymbicortBudesonide/Formoterol Fumarate | 73 | $24,213 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 87 | $14,912 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 274 | $12,055 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $6,564 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,448 |
| Roflumilast | 40 | $4,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $1,544 | $298,656362 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $236 | $153,20413 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $290 | $116,809190 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $281 | $67,34282 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Ocean Springs
- Sardar BabarOcean Springs$21K
- Jerrod TaylorOcean Springs$11K
- Subhas SitaulaOcean Springs$10K
- Aejaz Ul HaqOcean Springs$9K
- Syed Abdullah WaheedOcean Springs$8K
- Bishal GyawaliOcean Springs$7K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
- Michal SenitkoJackson$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.